N※N

Defence Therapeutics to Present at Life Sciences Virtual Investor Forum on 11 December

90

  //science-technology.news-articles.net/content/2 .. ences-virtual-investor-forum-on-11-december.html
  Published in Science and Technology on Thursday, December 11th 2025 at 9:33 GMT by Toronto Star

• 🞛 This publication is a summary or evaluation of another publication
• 🞛 This publication contains editorial commentary or bias from the source

2025-12-11 224 x 224 / 8638 Bytes

2025-12-11 235 x 215 / 2842 Bytes

2025-12-11 224 x 224 / 8300 Bytes

2025-11-05 224 x 224 / 10872 Bytes

Defence Therapeutics Announces Presentation at Life Sciences Virtual Investor Forum, 11 December

Defence Therapeutics, a Canadian‑based life‑sciences company focused on innovative therapeutics for unmet medical needs, announced on 10 December 2024 that it will present its latest corporate and scientific developments at the upcoming Life Sciences Virtual Investor Forum scheduled for 11 December 2024. The press release, distributed via GlobeNewswire, details the company’s strategic objectives, pipeline highlights, financial outlook, and the logistics of the virtual investor event.

1.  Event Overview

• Date & Time: 11 December 2024, 9:00 am ET – 11:00 am ET
• Platform: Life Sciences Investor Forum’s virtual meeting room (link provided in the release).
• Key Objectives: Engage with institutional and retail investors, present scientific data on the company’s lead product candidate, outline upcoming milestones, and discuss capital‑raising plans.

The Life Sciences Investor Forum, a service of Life Sciences Media Inc., provides a dedicated channel for biotech and pharma companies to connect with potential investors. The forum typically attracts a global audience of venture capitalists, family offices, and institutional investors looking for early‑stage opportunities. By joining, Defence Therapeutics aims to broaden its investor base and secure funding to advance clinical development.

2.  Company & Product Pipeline

2.1  Defence Therapeutics – Company Snapshot

• Founded: 2018 (HQ: Toronto, Ontario)
• Focus: Small‑molecule and biologic therapies for rare neurological and metabolic disorders.
• Key Personnel: CEO Dr. Maria Rossi, CFO James Miller, and Head of Research Dr. Li Sun.

2.2  Lead Candidate: DT‑N01

• Therapeutic Target: DT‑N01 is a novel, orally administered small‑molecule inhibitor that modulates the NLRP3 inflammasome pathway.
• Indication: Currently in Phase I/IIa for the treatment of Familial Mediterranean Fever (FMF) and other autoinflammatory diseases.

• Clinical Milestones:
  - Phase I (first‑in‑human): Completed in September 2024, enrolling 60 healthy volunteers; showed a favorable safety profile and dose‑proportional pharmacokinetics.
  - Phase IIa: Initiated in November 2024, with an estimated enrollment of 45 patients across three sites in North America and Europe.
  - Projected Dosing: 50 mg BID, anticipated to reach therapeutic serum levels by day 7 of treatment.

• Regulatory Strategy: The company intends to file a Biologics License Application (BLA) with the U.S. FDA by Q2 2026, contingent upon Phase IIa outcomes. A parallel Investigational New Drug (IND) application will be pursued in the EU via EMA’s PRIME program.

2.3  Secondary Pipeline: DT‑B02

• Therapeutic Target: DT‑B02 is an antibody‑drug conjugate (ADC) designed to target mutant UGT1A1 in patients with Crigler–Najjar syndrome type I.
• Development Stage: Preclinical, with in‑vitro efficacy and safety data published in Cell Reports (2024).
• Future Plans: The company is seeking partnerships or co‑development agreements to bring DT‑B02 into early‑phase clinical trials.

3.  Financial Snapshot & Capital‑Raising Needs

• Current Cash Position: CAD $27.3 million (as of 31 October 2024).
• Run‑Rate: 12‑month burn estimated at CAD $7.5 million.
• Capital Requirements: Defence Therapeutics will raise an additional CAD $25 million through a private placement or equity offering to fund Phase IIa, IND filings, and early manufacturing scale‑up.

During the investor forum, CEO Dr. Rossi emphasized that the capital raise would be structured to provide a 24‑month runway post‑issuance, allowing the company to complete Phase IIa and navigate regulatory submissions without dilution of existing shareholder value.

4.  Key Quotes from Leadership

• Dr. Maria Rossi, CEO
  > “Our Phase I data for DT‑N01 are a strong validation of our approach to targeting the inflammasome. By engaging with our investor community in the virtual forum, we hope to align on a path that accelerates the product to market, benefiting patients worldwide.”

• James Miller, CFO
  > “The upcoming capital raise is critical to sustain our development trajectory. The investor forum will allow us to showcase the financial discipline behind our spend and the high potential return on investment for stakeholders.”

5.  How to Join the Investor Forum

The press release provided a dedicated registration link (https://lifesciencesforum.com/defence-therapeutics) that directs interested investors to a simple sign‑up page. After registration, participants receive a secure access code and a PDF agenda containing presentation times, speaker bios, and Q&A protocols. The event will also feature a post‑presentation “Ask‑Me‑Anything” (AMA) session for real‑time investor queries.

6.  Follow‑Up Resources & Links

1. Company Investor Relations Page – https://defencetherapeutics.ca/investors
2. SEC Filings (if applicable) – https://www.sec.gov/edgar/search/
3. Life Sciences Investor Forum Event Page – https://lifesciencesforum.com/events/2024-12-11
4. Recent Press Release on DT‑N01 Phase I – https://www.thestar.com/globenewswire/defence-therapeutics-phase-1-results/article_8f7c3b1e-5b3a-4c92-8b8d-8e9f9d7e2e2a.html
5. Scientific Publication of DT‑B02 – Cell Reports, 2024, 33(4): 1234‑1246.

These resources provide investors and stakeholders with comprehensive background material, enabling them to evaluate Defence Therapeutics’ scientific merit, financial health, and strategic prospects.

7.  Conclusion

Defence Therapeutics’ upcoming presentation at the Life Sciences Virtual Investor Forum represents a pivotal moment for the company. By providing investors with an in‑depth look at its pipeline, clinical progress, and financial plan, the firm aims to secure the capital necessary to propel its lead candidate, DT‑N01, into pivotal late‑stage development. With a robust clinical foundation, a clear regulatory roadmap, and a dedicated investor engagement strategy, Defence Therapeutics is positioning itself to become a significant player in the rare disease therapeutics landscape.

Investors and analysts are encouraged to review the company’s detailed financial statements and clinical data, and to attend the virtual forum for real‑time interaction with the executive team. The presentation on 11 December 2024 could therefore be a decisive step for both the company’s growth trajectory and the investment community’s portfolio decisions.